BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Inhibikase Therapeutics 

3375 Spring Hill Parkway SE
Suite 811
Smyrna  Georgia  30080  U.S.A.
Phone: 917-494-0831 Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
Inhibikase Therapeutics Receives Orphan Drug Designation For Treatment Of Progressive Multifocal Leukoencephalopathy (PML) 5/21/2014 9:37:16 AM
Inhibikase Therapeutics Elects Anthony Zook To The Board Of Directors 11/21/2013 6:59:15 AM
Inhibikase Therapeutics to Present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 5/23/2013 6:45:43 AM
Inhibikase Therapeutics to Present at 5th International Congress on Polyomaviruses and Human Diseases 4/25/2013 7:33:42 AM
Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors 3/9/2012 10:01:19 AM
Bristol-Myers Squibb Company (BMY) Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibikase Therapeutics 2/3/2012 6:40:37 AM
Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients 8/16/2011 11:03:06 AM
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors 5/17/2011 9:23:14 AM
Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009 10/26/2009 8:36:11 AM